Berzosertib联合拓扑替康对比拓扑替康单药治疗复发性小细胞肺癌:一项随机临床试验
这项开放标签2期随机临床试验自2019年12月1日至2022年12月31日从16个美国癌症中心入组60例经≥1线治疗后复发的SCLC患者,随机接受拓扑替康单药(20例)或拓扑替康联合berzosertib(40例)。联合组无进展生存期与单药组无显著差异(中位3.9 vs 3.0个月;HR 0.80,P=0.44),但总生存期显著延长(中位8.9 vs 5.4个月;HR 0.53,P=0.03)。
要点
- 拓扑替康联合berzosertib未改善复发性SCLC的无进展生存期(HR 0.80,95%CI 0.46-1.41,P=0.44)。
- 联合组总生存期显著长于拓扑替康单药组(中位8.9 vs 5.4个月;HR 0.53,95%CI 0.29-0.96,P=0.03)。
- 两组不良事件谱相似,如3/4级血小板减少分别为50%与55%。
核心结论
- 在复发性小细胞肺癌患者中,与拓扑替康单药相比,berzosertib联合拓扑替康未改善无进展生存期,但显著改善了总生存期。
研究设计与样本
- 开放标签2期随机临床试验,于2019年12月1日至2022年12月31日从16个美国癌症中心入组60例经1线或以上治疗后复发的SCLC患者,按一线铂类化疗敏感性分层随机。
- 患者随机分配至拓扑替康单药组(20例,1.25 mg/m2静脉给药,第1至5天)或联合berzosertib组(40例,拓扑替康同上,berzosertib 210 mg/m2静脉给药,第2天和第5天),21天为一周期。
主要发现
- 中位随访21.3个月(IQR 18.1-28.3),联合组与单药组的中位无进展生存期分别为3.9个月(95%CI 2.8-4.6)与3.0个月(95%CI 1.2-5.1),HR 0.80(95%CI 0.46-1.41),P=0.44,无显著差异。
- 联合组与单药组的中位总生存期分别为8.9个月(95%CI 4.8-11.4)与5.4个月(95%CI 3.2-6.8),HR 0.53(95%CI 0.29-0.96),P=0.03,联合组显著延长。
- 两组不良事件谱相似:3/4级血小板减少单药组11/20(55%)、联合组20/40(50%);任何级别恶心单药组9/20(45%)、联合组14/40(35%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with relapsed small cell lung cancer (SCLC), a high replication stress tumor, have poor prognoses and few therapeutic options. A phase 2 study showed antitumor activity with the addition of the ataxia telangiectasia and Rad3-related kinase inhibitor berzosertib to topotecan. OBJECTIVE: To investigate whether the addition of berzosertib to topotecan improves clinical outcomes for patients with relapsed SCLC. DESIGN, SETTING, AND PARTICIPANTS: Between December 1, 2019, and December 31, 2022, this open-label phase 2 randomized clinical trial recruited 60 patients with SCLC and relapse after 1 or more prior therapies from 16 US cancer centers. Patients previously treated with topotecan were not eligible. INTERVENTIONS: Eligible patients were randomly assigned to receive topotecan alone (group 1), 1.25 mg/m2 intravenously on days 1 through 5, or with berzosertib (group 2), 210 mg/m2 intravenously on days 2 and 5, in 21-day cycles. Randomization was stratified by tumor sensitivity to first-line platinum-based chemotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS) in the intention-to-treat population. Secondary end points included overall survival (OS) in the overall population and among patients with platinum-sensitive or platinum-resistant tumors. The PFS and OS for each treatment group were estimated using the Kaplan-Meier method. The log-rank test was used to compare PFS and OS between the 2 groups, and Cox proportional hazards models were used to estimate the treatment hazard ratios (HRs) and the corresponding 2-sided 95% CI. RESULTS: Of 60 patients (median [range] age, 59 [34-79] years; 33 [55%] male) included in this study, 20 were randomly assigned to receive topotecan alone and 40 to receive a combination of topotecan with berzosertib. After a median (IQR) follow-up of 21.3 (18.1-28.3) months, there was no difference in PFS between the 2 groups (median, 3.0 [95% CI, 1.2-5.1] months for group 1 vs 3.9 [95% CI, 2.8-4.6] months for group 2; HR, 0.80 [95% CI, 0.46-1.41]; P = .44). Overall survival was significantly longer with the combination therapy (5.4 [95% CI, 3.2-6.8] months vs 8.9 [95% CI, 4.8-11.4] months; HR, 0.53 [95% CI, 0.29-0.96], P = .03). Adverse event profiles were similar between the 2 groups (eg, grade 3 or 4 thrombocytopenia, 11 of 20 [55%] vs 20 of 40 [50%], and any grade nausea, 9 of 20 [45%] vs 14 of 40 [35%]). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, treatment with berzosertib plus topotecan did not improve PFS compared with topotecan therapy alone among patients with relapsed SCLC. However, the combination treatment significantly improved OS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03896503.
引用
- Takahashi N, Hao Z, Villaruz LC, et al. Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37824137. doi:10.1001/jamaoncol.2023.4025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。